TRANSCODE THERAPEUTICS INC (RNAZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.60+1.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RNAZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
RNAZ — legal / regulatory event — Triggering Events That Accelerate or Increase a Direct Financial Obligation o…
Dated 2026-10-01
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement The information set forth in
Why it matters: Phase 1a results showed stable disease in 10 of 14 patients. The larger trial must show whether that signal holds in colorectal cancer.
Supportive ifPhase 2a data show stable disease or better in a clear share of patients, with results reported by the trial team.
Worry ifPhase 2a data show disease progress in most treated patients. Or, the company says the early signal did not last.
Why it matters: The trial needs ctDNA-positive patients after colorectal cancer treatment. Better patient finding could help the study enroll.
Supportive ifA company update gives an enrollment count or says Phase 2a enrollment is complete for up to 45 patients.
Worry ifA company update reports slow enrollment or a trial delay. It may also report fewer than 45 planned patients enrolled by the target date.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$375 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $862 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,744 loss on $10,000 · 87.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.